STOCK TITAN

Candel Therapeutics (NASDAQ: CADL) director awarded 32,000 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Candel Therapeutics director Edward J. Benz Jr. received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.

The award is subject to time-based vesting, becoming exercisable on the earlier of June 23, 2027 or the next Annual Meeting of Stockholders, as long as he continues serving on the board unless the board decides otherwise. Following this grant, he holds 32,000 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Benz Edward J. JR
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 32,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 32,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 32,000 options Stock Option (Right to Buy) grant on June 23, 2026
Exercise price $9.08 per share Conversion/exercise price of granted stock options
Expiration date June 23, 2036 Option expiration for 32,000-share grant
Underlying shares 32,000 shares Common stock underlying the stock option grant
Post-grant option holdings 32,000 options Total stock options held following this transaction
Vesting date trigger June 23, 2027 Time-based vesting, or earlier next Annual Meeting of Stockholders
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
time-based vesting financial
"This option is subject to time-based vesting."
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
Board of Directors financial
"resigns from the Board of Directors (the "Board") of the Issuer"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
derivative securities financial
"Grant, award, or other acquisition of derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Benz Edward J. JR

(Last)(First)(Middle)
C/O CANDEL THERAPEUTICS, INC.
117 KENDRICK ST., SUITE 450

(Street)
NEEDHAM MASSACHUSETTS 02494

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$9.0806/23/2026A32,000 (1)06/23/2036Common Stock32,000$032,000D
Explanation of Responses:
1. This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
/s/ Charles Schoch, as Attorney-In-Fact for Edward J. Benz Jr.06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Candel Therapeutics (CADL) report for Edward J. Benz Jr.?

Candel Therapeutics reported that director Edward J. Benz Jr. received a grant of stock options for 32,000 shares. These options are a compensation award, not an open-market purchase or sale, and give him the right to buy common stock at a fixed exercise price.

What is the exercise price of the new CADL stock options granted to the director?

The granted stock options have an exercise price of $9.08 per share. This means the director can buy Candel Therapeutics common stock at $9.08 if the options vest and are exercised before they expire in 2036, regardless of the market price at that time.

When do Edward J. Benz Jr.’s CADL stock options vest?

The options vest on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders. Vesting also depends on his continued service on Candel Therapeutics’ board, unless the board determines vesting should continue despite a change in his status.

When do the newly granted CADL stock options expire?

The stock options granted to Edward J. Benz Jr. expire on June 23, 2036. If they are not exercised by that date, the right to purchase 32,000 shares at the $9.08 exercise price will lapse and the options will no longer be exercisable.

How many CADL stock options does the director hold after this Form 4 transaction?

After this transaction, Edward J. Benz Jr. holds 32,000 stock options directly. All of these options relate to Candel Therapeutics common stock and are subject to the time-based vesting conditions and the 2036 expiration date described in the Form 4 filing.

Is the CADL Form 4 transaction an open-market buy or sell of shares?

No, the Form 4 reports a grant of stock options as compensation, not an open-market trade. The transaction code is “A,” indicating an award or other acquisition of derivative securities, giving the director the right to buy shares in the future if the options vest.